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Allergic contact dermatitis (ACD) is a common skin disease in people and may become a potential site of exposure
to nanoparticles (NP). Silica nanoparticles (SiO2-NP) possess a promising potential for various medical and non-medical
applications, including normal and diseased skin as target organs. However, it has been shown that negatively charged
SiO2-NP may act as proinflammatory adjuvant in allergic diseases. The effect of topical SiO2-NP exposure on preexisting
ACD has not been studied to date although this reflects a common in vivo situation. Of particular interest are the
potential effects of positively charged N-(6-aminohexyl)-aminopropyltrimethoxysilane (AHAPS)-functionalized SiO2-NP
which are promising candidates for delivery systems, including gene delivery into the skin. Here, the effects of such
AHAPS-functionalized SiO2-NP (55 ± 6 nm in diameter) were studied in an oxazolone-induced ACD model in SKH1 mice
and compared to ACD mice treated with vehicle only. The clinical course of the disease was assessed by monitoring of
the transepidermal water loss (TEWL) and the erythema. In histologic and morphometric analyses, the distribution of
particles, the degree of inflammation, epidermal thickness, and the inflammatory infiltrate were characterized and
quantified by standard and special histological stains as well as immunohistochemistry for CD3+ lymphocytes.
To assess possible systemic effects, serum immunoglobulin E (IgE) was determined by enzyme-linked immunosorbent
assay. Following administration of AHAPS-SiO2-NP for five consecutive days, no effects were observed in all clinical,
histologic, morphometric, and molecular parameters investigated. In conclusion, positively charged AHAPS-SiO2-NP
seem not to affect the course of ACD during exposure for 5 days.
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Silica nanoparticles (SiO2-NP) are among the most
promising inorganic nanoparticles (NP) for biomedical
applications, such as drug and gene delivery systems,
including vaccination [1,2]. In addition, they are used
in everyday products like cosmetics [3].
Several studies have shown pro-inflammatory adjuvant
effects of SiO2-NP during ovalbumin or mite antigen-
induced allergic dermatitis and allergic airway disease
when NP and antigen were administered simultaneously
as immunogenic challenge [4-8]. However, no study has
addressed possible effects of intended or unintended
NP exposure in an already existing allergic contact* Correspondence: achim.gruber@fu-berlin.de
1Institute of Veterinary Pathology, Freie Universität Berlin,
Robert-von-Ostertag-Str. 15, 14163 Berlin, Germany
Full list of author information is available at the end of the article
© 2014 Ostrowski et al.; licensee Springer. This
Attribution License (http://creativecommons.or
in any medium, provided the original work is pdermatitis (ACD) which affects approximately 20% of
European and North American people [9].
To date, the in vivo adjuvant effects of SiO2-NP in
allergic disease models have only been studied for nega-
tively charged SiO2-NP, including unfunctionalized and
polyethylene glycol (PEG)-functionalized SiO2-NP [4-8].
However, zeta potentials indicative of biologically relevant
surface charges have not always been reported in these
studies. The surface charge of NP and thus several aspects
of their performance in bioenvironments can largely be
modified by different functionalizations [10]. For example,
surface functionalization of SiO2-NP may drastically
reduce their in vitro and in vivo cytotoxicity compared
to unfunctionalized SiO2-NP [10,11]. Moreover, positively
charged N-(6-aminohexyl)-aminopropyltrimethoxysilane
(AHAPS)-functionalization results in increased colloidal
stability compared to unfunctionalized SiO2-NP and
markedly reduces its tendency towards aggregation [12].is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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surface functionalization may also influence NP behavior
in diseased tissues, including ACD. Furthermore, AHAPS-
functionalization with positive surface charge also allows
for additional applications, including DNA binding for
gene delivery or vaccination approaches [13]. However,
such particles have not been tested in an ACD environ-
ment to date.
Consequently, in the present study, we investigated
the effects of positively charged AHAPS-SiO2-NP in a
murine model of acute oxazolone-induced ACD [14].
Methods
Particle synthesis and characterization
Spherical SiO2-NP with a diameter of 55 ± 6 nm were
grown in a seeded growth process around a fluorescein-
5-isothiocyanate (FITC)-labeled SiO2-NP core as reported
previously [15,16]. Surface functionalization with AHAPS
bearing one primary and one secondary amino group per
molecule resulted in NP of high colloidal stability [12] and
changed the zeta potential of the SiO2-NP from highly
negative −45 ± 4 mV to highly positive values +37 ± 2 mV.
Well-dispersed AHAPS-SiO2-NP were transferred to
ultra-pure water (AlleMan Pharma, Pfullingen, Germany)
and remained colloidally stable as indicated by transmis-
sion electron microscopy (Figure 1) as well as dynamic
light scattering (DLS) measurements of hydrodynamic
diameter and zeta potential as previously shown [17].
Animals and study protocol
The study protocol was approved by the State Office of
Health and Social Affairs, Berlin (LAGeSo G 0209/11)Figure 1 Dispersion characteristics of AHAPS-SiO2 nanoparticles.
Transmission electron microscopy revealed well-dispersed FITC-labeled
AHAPS-SiO2-NP with a diameter of 55 ± 6 nm.and adhered to national guidelines. ACD was induced in
6- to 8-week-old, male mice of the outbred SKH1 strain
(n = 5; Charles River, Germany) using topical application
of oxazolone (Ox; Sigma-Aldrich, Steinheim, Germany)
in acetone (Biesterfeld Chemiedistribution, Hamburg,
Germany). The animals were sensitized with 1.5% Ox in
acetone on the right flank. One week later, a first chal-
lenge with 0.5% Ox in acetone was applied to the right
flank, followed by a second challenge with 0.5% Ox in
acetone 2 days later. Each animal was treated on five
consecutive days with 50 μL AHAPS-SiO2-NP (c = 5 g/L)
or ultra-pure water, respectively, per day starting 12 h fol-
lowing the first challenge as previously described in [17].
A solvent group (n = 3) was treated with acetone only to
control the effects of Ox. Prior to each treatment, the
transepidermal water loss (TEWL) was measured to assess
the skin barrier disruption with a Tewameter TM 300
(Courage + Khazaka, Cologne, Germany) as described in
[18]. Erythema was determined macroscopically and a
photograph was taken daily with a digital camera (NEX-3,
Sony, Tokyo, Japan). Twenty-four hours after the last
treatment, animals were euthanized and tissues were sam-
pled as described in [17].IgE measurements
Blood samples were collected by cardiac puncture immedi-
ately following euthanasia and serum immunoglobulin
E (IgE) concentrations determined with a mouse IgE
enzyme-linked immunosorbent assay (ELISA) quantifi-
cation kit (Bethyl Laboratories, Montgomery, TX, USA)
according to the manufacturer's protocol [19].Particle localization and histologic and morphometric
analyses
Fluorescent AHAPS-SiO2-NP were localized in 4′,6-
diamidino-2-phenylindole (DAPI; Carl Roth, Karlsruhe,
Germany) stained section as described in [17]. Further-
more, serial 5-μm sections of formalin-fixed, paraffin-
embedded skin were stained following routine protocols
with hematoxylin and eosin (HE) and toluidine blue or
Congo red for visualization of mast cells or eosinophils,
respectively. T lymphocytes were immunohistochemically
identified in lesional skin using antibodies to the surface
marker CD3 (rabbit polyclonal anti-human CD3, dilution
1:1,500, Dako, Glostrup, Denmark) following heat-induced
antigen retrieval with citrate buffer (pH 6.0) as reported
in [20].
Samples were examined microscopically using a BX41
microscope (Olympus, Shinjuku-ku, Japan) equipped with
a digital camera (Color-View II, SIS, Münster, Germany), a
fluorescence burner (U-RLF-T, Olympus, Japan), and a
digital image analysis software (AnalySIS docu, version
5.0, SIS, Münster, Germany). Tissues were evaluated
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observer-blinded manner as described below.
Histologic analysis of lesional skin included the evalu-
ation of hyperkeratosis, parakeratosis, intraepidermal exo-
cytosis, and dermal infiltrate. Epidermal thickness was
measured in six randomly selected lesional areas from the
basement membrane to the base of the stratum corneum
as described in [21]. Mast cells and eosinophils were
counted in 20 randomly selected high-power fields (hpf)
at × 400 magnification. T lymphocytes were counted in 10
hpf per epidermis and dermis, respectively.
Statistical analyses
Data are presented as mean ± standard error of the mean
(SEM). Statistical analyses were performed with SPSS soft-
ware (IBM, Armonk, NY, USA) using one-way ANOVA for
normally distributed parameters (IgE, epidermal thickness,
and CD3+ cells) or Kruskal-Wallis test for not normally
distributed parameters (mast cells and eosinophils). For
all tests, significance was considered for p < 0.05 with
the following designation: *p < 0.05 and ***p < 0.001.
Results
Clinically, the Ox treatment resulted in a marked increase
in TEWL values, independently of subsequent treatment
with AHAPS-SiO2-NP or vehicle alone (Figure 2A). TheFigure 2 Effects of AHAPS-SiO2-NP treatments on barrier
function and erythema. Transepidermal water loss (TEWL)
increased in oxazolone (Ox)-treated mice without significant
differences between the AHAPS-SiO2-NP-treated versus ultra-pure
water-treated groups. Solvent-only-treated mice failed to develop
elevated TEWL values above the physiological threshold (A). Erythema
was absent from the skin of the acetone solvent group (B) but present
to similar degrees in the vehicle control group (C) and AHAPS-SiO2-
NP-treated group (D). Data are presented as mean ± SEM; Ox-treated
groups: n = 5; solvent-treated group: n = 3.highest values were recorded on treatment day 5 without
significant differences between the two treatment groups
(AHAPS-SiO2-NP versus ultra-pure water). Treatment of
the skin with acetone alone did not increase TEWL values,
and values remained within physiological ranges below
10 g/m2h [18]. Ox-treated skin but not the skin in the
acetone solvent group developed a marked erythema
beginning 12 h after the first Ox challenge and lasting
for the whole treatment period (Figure 2B,C,D). Consist-
ently, significant higher final serum IgE concentrations
were recorded in Ox-treated mice compared to mice from
the control group (Figure 3). There were no statistically
significant differences between the AHAPS-SiO2-NP
(176.69 ± 36.83 ng/mL) and vehicle (292.14 ± 150.59 ng/mL)
treatments.
Using fluorescence microscopy of skin sections, the
green fluorescent AHAPS-SiO2-NP were localized only
in the superficial layers of the stratum corneum in all
particle-treated mice as shown earlier [17]. No fluorescent
signal was detected in the stratum corneum of ultra-pure
water-treated animals.
Histologically, the lesional skin of ACD mice showed a
mild hyperkeratosis and a severe intraepithelial exocytosis
as well as dermal infiltrates. Parakeratosis was minimal in
Ox-treated animals. Mice treated with acetone solvent
only did not show any histopathological changes. No dif-
ferences in the histologic parameters were seen between
both treatment groups of ACD (Figure 4A,B,C). Morpho-
metrically, the epidermis in Ox-induced ACD was signifi-
cantly thicker compared to that from mice of the solvent
group. In contrast, no significant differences were re-
corded between epidermal thicknesses in AHAPS-SiO2-
NP-treated versus vehicle-treated ACD mice (Figure 4A,B,Figure 3 Serum IgE response following topical oxazolone
treatment. Serum IgE levels were significantly different between the
acetone solvent control and oxazolone (Ox)-treated groups but without
significant differences between the vehicle and AHAPS-SiO2-NP
treatments. Data are presented as a box plot with whiskers displaying
minimum to maximum values; Ox-treated groups: n= 5; solvent-treated
group: n= 3; *p< 0.05, ***p< 0.001.
Figure 4 Histologic and morphometric analyses of lesional skin. Hematoxylin and eosin (HE) staining and measurement of epidermal
thickness indicated by brackets (top panel) failed to reveal inflammation-associated epidermal thickening in solvent controls (A) but showed
marked thickening of the epidermis and intraepidermal immune cell exocytosis in oxazolone (Ox)-treated mice without differences between the
vehicle control and AHAPS-SiO2-NP treatments (B-D). Increased infiltrations with mast cells (toluidine blue, central horizontal panel: E-H) and
eosinophils (Congo red, bottom panel: I-L, arrows) were very similar between the two Ox-treated groups. Only a few mast cells and eosinophils
were observed in acetone solvent controls (E, I). Images represent typical samples. Quantification included all samples in panels D, H, and L. Data
are presented as mean ± SEM; Ox-treated groups: n = 5; solvent-treated group: n = 3; ***p < 0.001.
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mast cells and eosinophils (Figure 4E,F,G,H,I,J,K,L) as well
as for T lymphocytes infiltrating the epidermis and dermis
(Figure 5). The data of each group for all morphometric,
histologic, and immunohistochemical parameters are
summarized in Table 1.
Discussion
In contrast to previous studies according to which skin
barrier disruptions result in increased penetration of
irritants with aggravation of inflammatory disease [22],
we could not detect any effects of AHAPS-SiO2-NP on
the quality or degree of inflammation. Specifically, our
results are at variance with previous studies using nega-
tively charged SiO2-NP that had aggravated allergic reac-
tions in the skin and airways including the same dose asused here [4-8]. Among possible explanations of this dis-
crepancy is the fact that AHAPS-SiO2-NP do not pene-
trate beyond the stratum corneum, the outermost layer of
the skin, in normal and irritated skin, including the mice
used here. The distribution and levels of penetration of
AHAPS-SiO2-NP on the skin of ACD mice have been
studied in detail in a previous report of our group [17]. In
that study, no pathological changes were recorded in
healthy mice following exposure to AHAPS-SiO2-NP [17].
Furthermore, NP had been injected intradermally in the
majority of previous studies [5,6]. Consequently, in these
studies, the SiO2-NP reach viable epidermal layers and
may directly interact with keratinocytes and immune cells.
Thus, an injection poorly models the in vivo situation
in human and murine ACD where NP are topically ap-
plied to the skin and have to overcome the relatively
Figure 5 Quantification of T lymphocytes. Cellular infiltrates of the skin in acute contact dermatitis were mainly attributed to T lymphocytes as
identified immunohistochemically by the detection of CD3 antigen and visualized with the brown chromogen diaminobenzidine. Nuclei were
counterstained with hemalaun. Significant differences were observed only between the acetone solvent control (A) and oxazolone (Ox)-treated
groups but not between the vehicle control (B) and AHAPS-SiO2-NP-treated groups (C). The same quantitative effects were seen for T lymphocytic
infiltration into the epidermis (D) and dermis (E). Data are presented as mean ± SEM; Ox-treated groups: n= 5; solvent-treated group: n= 3; ***p< 0.001.
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thickness is increased due to hyperkeratosis. External, top-
ical application of NP was reported only in a single study
so far [7] in which a mild aggravation of skin lesions was
observed. However, in that study, the SiO2-NP were ap-
plied simultaneously with mite antigen over a 4-week
period with three applications per week. So far, the effects
of topical SiO2-NP exposure to an already existing ACD
have not been studied although ACD is a common skin
disorder in Western European and North American
people with a prevalence of about 20% [9]. As reported by
several studies, even higher values for IgE, mast cells,Table 1 Morphometry and quantification of data from lesiona
Solvent
Epidermal thickness [μm] 23.04 ± 1.21
Mast cellsa 14.08 ± 0.51
Eosinophilsa 0.93 ± 0.12
T lymphocytesa in the epidermis 23.33 ± 1.05
T lymphocytesa in the dermis 38.63 ± 1.33
aNumber of cells per high-power field (hpf), counted in at least 10 hpf. Epidermal th
CD3+ T lymphocytes in the epidermis and dermis of lesional skin expressed as meaeosinophils, and CD3-positive cells could have been ex-
pected in inflamed mouse skin. It therefore seems likely
that NP-induced aggravation of the ACD would still have
been detectable in the background of our Ox-induced in-
flammation [5,24-26]. Furthermore, it has been shown
that surface functionalization improves the biocompati-
bility of SiO2-NP [10,11]. Therefore, both the failure of
penetrating beyond the stratum corneum and the improved
biocompatibility due to functionalization may have pre-
vented the aggravation of barrier defects and inflammatory
response in our study. However, we cannot exclude the
possibility that effects would have occurred if significantlyl skin
Oxazolone + H2O Oxazolone + AHAPS-SiO2-NP
68.95 ± 1.7 61.84 ± 2.58
25.34 ± 0.9 23.84 ± 0.86
8.30 ± 0.24 7.63 ± 0.23
161.36 ± 3.87 160.52 ± 3.65
151.52 ± 3.19 142.54 ± 2.71
ickness measurements and quantification of mast cells, eosinophils, and
n ± SEM.
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here appears to reflect a realistic condition and offers opti-
mal comparability with the previous studies on unfunctio-
nalized and functionalized SiO2-NP [5,8,17].
In addition, the specific model used here for the
induction of ACD may have had an effect on the results.
Ox-induced dermatitis cannot be strictly classified as
either T helper (Th)1- or Th2-dominated response [27].
In contrast, ovalbumin and mite antigens result in
specifically Th2-driven allergic dermatitis. However, the
specific roles of the immune mechanisms involved, both
in terms of induction of the hypersensitivity reaction
and the exacerbation of allergic disease by certain NP
other than AHAPS-SiO2-NP, need to be studied in the
future.Conclusions
Taken together, our data show that AHAPS-SiO2-NP
exposure to diseased skin in an ACD model does not
affect the course and outcome of the disease over 5 days.
It thus seems that a short-time exposure of AHAPS-
SiO2-NP to mouse skin is without any pathological
consequences, at least as far as can be judged with the
techniques employed here. The reasons why the AHAPS-
functionalized NP do not modulate barrier disruption or
inflammatory responses as seen in other allergic disease
models and whether the observations hold true in a long-
term exposure model should be addressed in the future.
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